Correction to: Mol Cancer 19, 90 (2020)

https://doi.org/10.1186/s12943-020-01202-9

Following the publication of the original paper [1], the authors found minor typographical errors that should be corrected.

In the Results section, the dosage of ASK120067 in the sentence “we present a preliminary result of a patient in this clinical study with a confirmed radiographic response after treatment with the lowest dose (40 mg/kg once daily)” has been corrected to “…with the lowest dose (40 mg once daily)”.

In the figure legend of Figure 3g, the sentence “Computed tomography scans of the chest from a patient before and after treatment with 40 mg/kg ASK120067 in a phase I trial…” has been corrected to “…treatment with 40 mg ASK120067 once daily in a phase I trial…”.

These corrections have no impact on the results or conclusions of the study.

The original article has been corrected.

1. 1.

   Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90. https://doi.org/10.1186/s12943-020-01202-9.

   CAS Article PubMed PubMed Central Google Scholar

Download references

1. Tao Zhang, Rong Qu, and Shingpan Chan contributed equally to this work.

Affiliations

1. Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China

   Tao Zhang, Rong Qu, Mengzhen Lai, Linjiang Tong, Fang Feng, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Jian Ding & Hua Xie

2. International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China

   Shingpan Chan & Ke Ding

3. School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China

   Mengzhen Lai & Yingqiang Liu

4. Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm), 699 Kejian Road, Nanjing, 211112, China

   Hongyu Chen & Tingting Song

5. University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing, 100049, China

   Gang Bai

6. School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China

   Gang Bai

1. Tao ZhangView author publications

   You can also search for this author in PubMed Google Scholar

2. Rong QuView author publications

   You can also search for this author in PubMed Google Scholar

3. Shingpan ChanView author publications

   You can also search for this author in PubMed Google Scholar

4. Mengzhen LaiView author publications

   You can also search for this author in PubMed Google Scholar

5. Linjiang TongView author publications

   You can also search for this author in PubMed Google Scholar

6. Fang FengView author publications

   You can also search for this author in PubMed Google Scholar

7. Hongyu ChenView author publications

   You can also search for this author in PubMed Google Scholar

8. Tingting SongView author publications

   You can also search for this author in PubMed Google Scholar

9. Peiran SongView author publications

   You can also search for this author in PubMed Google Scholar

10. Gang BaiView author publications

    You can also search for this author in PubMed Google Scholar

11. Yingqiang LiuView author publications

    You can also search for this author in PubMed Google Scholar

12. Yanan WangView author publications

    You can also search for this author in PubMed Google Scholar

13. Yan LiView author publications

    You can also search for this author in PubMed Google Scholar

14. Yi SuView author publications

    You can also search for this author in PubMed Google Scholar

15. Yanyan ShenView author publications

    You can also search for this author in PubMed Google Scholar

16. Yiming SunView author publications

    You can also search for this author in PubMed Google Scholar

17. Yi ChenView author publications

    You can also search for this author in PubMed Google Scholar

18. Meiyu GengView author publications

    You can also search for this author in PubMed Google Scholar

19. Ke DingView author publications

    You can also search for this author in PubMed Google Scholar

20. Jian DingView author publications

    You can also search for this author in PubMed Google Scholar

21. Hua XieView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ke Ding or Jian Ding or Hua Xie.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Cite this article

Zhang, T., Qu, R., Chan, S. et al. Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer 20, 102 (2021). https://doi.org/10.1186/s12943-021-01391-x

Download citation

• Published: 17 August 2021

• DOI: https://doi.org/10.1186/s12943-021-01391-x